

Memory Pharmaceuticals stock up after delayed IPO

Tuesday April 6, 1:15 PM EDT

NEW YORK, April 6 (Reuters) - Shares of Memory Pharmaceuticals Corp. ([MEMY](#)), which develops drugs for central nervous system disorders, surged on Tuesday after an initial public offering that had been delayed for two weeks amid weakness in the pharmaceutical sector.

In early afternoon trading on Nasdaq, the stock was selling for \$10.29, up \$1.89 or 22.5 percent. The stock had begun trading late on Monday immediately after the IPO was priced at \$7 per share and closed the day up 23 percent at \$8.40.

The Montvale, New Jersey-based company had originally estimated the IPO of 5 million shares would sell for \$13-\$15 per share. It had expected the deal to be done on March 24.

But weakness in the pharmaceutical and biotech sector forced the underwriters to delay the IPO and eventually lower the offering price to \$7 per share. At the time, other offerings, such as Santarus([SNTS](#)), Anadys Pharmaceuticals ([ANDS](#)), Xcyte Therapies([XCYT](#)) and Tercica ([TRCA](#)) all lowered IPO price ranges substantially before launching.

UBS Securities, SG Cowen, Banc of America Securities and Fortis Securities underwrote the IPO for Memory, which specializes in drugs treating disorders that include neurological diseases like Alzheimer's, vascular dementia and schizophrenia.